{"title":"根据临床症状和化疗评估乳腺癌患者血液中的 miRNA 含量。","authors":"О Harashchenko","doi":"10.15407/exp-oncology.2023.04.451","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) stands out as the most prevalent cancer in women. The levels of miRNA expression before and after chemotherapy are considered a potential indicator for the prognosis of the disease.</p><p><strong>Aim: </strong>To study blood plasma miRNA levels in BC patients and to assess their correlation with the menopausal status, disease stage, and molecular BC subtype.</p><p><strong>Materials and methods: </strong>Blood plasma levels of 6 miRNAs (miRNA-25, miRNA-27, miRNA-155, miRNA-200, miRNA-335, and miRNA-497) were studied in 70 BC patients and 18 healthy individuals using RT-PCR.</p><p><strong>Results: </strong>miRNA-25, miRNA-335, and miRNA-497 levels were significantly higher in BC patients, while a tendency toward a decrease in the miRNA-27 and miRNA-335 levels in premenopausal patients and high miRNA-27 levels in menopausal patients was established. After neoadjuvant chemotherapy, a decrease in the miRNA-25 and miRNA-335 levels was registered.</p><p><strong>Conclusions: </strong>The results indicated that miRNA-25, miRNA-27, miRNA-335, and miRNA-497 deserve attention as markers for assessing the efficacy of treatment of BC patients.</p>","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"45 4","pages":"451-456"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ASSESSMENT OF CIRCULATING miRNA LEVELS IN BREAST CANCER PATIENTS DEPENDING ON CLINICAL CHARACTERISTICS AND CHEMOTHERAPY.\",\"authors\":\"О Harashchenko\",\"doi\":\"10.15407/exp-oncology.2023.04.451\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Breast cancer (BC) stands out as the most prevalent cancer in women. The levels of miRNA expression before and after chemotherapy are considered a potential indicator for the prognosis of the disease.</p><p><strong>Aim: </strong>To study blood plasma miRNA levels in BC patients and to assess their correlation with the menopausal status, disease stage, and molecular BC subtype.</p><p><strong>Materials and methods: </strong>Blood plasma levels of 6 miRNAs (miRNA-25, miRNA-27, miRNA-155, miRNA-200, miRNA-335, and miRNA-497) were studied in 70 BC patients and 18 healthy individuals using RT-PCR.</p><p><strong>Results: </strong>miRNA-25, miRNA-335, and miRNA-497 levels were significantly higher in BC patients, while a tendency toward a decrease in the miRNA-27 and miRNA-335 levels in premenopausal patients and high miRNA-27 levels in menopausal patients was established. After neoadjuvant chemotherapy, a decrease in the miRNA-25 and miRNA-335 levels was registered.</p><p><strong>Conclusions: </strong>The results indicated that miRNA-25, miRNA-27, miRNA-335, and miRNA-497 deserve attention as markers for assessing the efficacy of treatment of BC patients.</p>\",\"PeriodicalId\":94318,\"journal\":{\"name\":\"Experimental oncology\",\"volume\":\"45 4\",\"pages\":\"451-456\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15407/exp-oncology.2023.04.451\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15407/exp-oncology.2023.04.451","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景：乳腺癌（BC）是女性发病率最高的癌症。目的：研究乳腺癌患者的血浆 miRNA 水平，并评估其与绝经状态、疾病分期和分子 BC 亚型的相关性：采用RT-PCR方法研究了70名BC患者和18名健康人血浆中6种miRNA（miRNA-25、miRNA-27、miRNA-155、miRNA-200、miRNA-335和miRNA-497）的水平。结果发现：在 BC 患者中，miRNA-25、miRNA-335 和 miRNA-497 的水平明显较高，而在绝经前患者中，miRNA-27 和 miRNA-335 的水平呈下降趋势，在绝经期患者中，miRNA-27 的水平较高。新辅助化疗后，miRNA-25和miRNA-335水平有所下降：结果表明，miRNA-25、miRNA-27、miRNA-335和miRNA-497作为评估BC患者疗效的标志物值得关注。
ASSESSMENT OF CIRCULATING miRNA LEVELS IN BREAST CANCER PATIENTS DEPENDING ON CLINICAL CHARACTERISTICS AND CHEMOTHERAPY.
Background: Breast cancer (BC) stands out as the most prevalent cancer in women. The levels of miRNA expression before and after chemotherapy are considered a potential indicator for the prognosis of the disease.
Aim: To study blood plasma miRNA levels in BC patients and to assess their correlation with the menopausal status, disease stage, and molecular BC subtype.
Materials and methods: Blood plasma levels of 6 miRNAs (miRNA-25, miRNA-27, miRNA-155, miRNA-200, miRNA-335, and miRNA-497) were studied in 70 BC patients and 18 healthy individuals using RT-PCR.
Results: miRNA-25, miRNA-335, and miRNA-497 levels were significantly higher in BC patients, while a tendency toward a decrease in the miRNA-27 and miRNA-335 levels in premenopausal patients and high miRNA-27 levels in menopausal patients was established. After neoadjuvant chemotherapy, a decrease in the miRNA-25 and miRNA-335 levels was registered.
Conclusions: The results indicated that miRNA-25, miRNA-27, miRNA-335, and miRNA-497 deserve attention as markers for assessing the efficacy of treatment of BC patients.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
